Abstract
To evaluate the pharmacoeconomics of three therapeutic schemes in treating anti-tuberluosis therapy -induced liver injury (anti-TB DILI).MethodsIn the construction of a decision tree model, the efficacy and safety parameters came from the results of the randomized, controlled trial conducted here, the effect parameters were derived from expert advice, and the cost parameters, such as usage specification, number, and unit price, came from literature, expert advice, and so on.ResultsThe cost-effectiveness analysis (CEA) based on the effect degrees showed that bicyclol had the best effect (4.63562). The incremental cost-effectiveness ratio (ICER) (206.03270) of bicyclol was the lowest. The cost-effectiveness ratio of silibinin was the lowest (68.59987). The CEA based on the complete normalization rate showed that bicyclol had the highest complete normalization rate (83.562%), the lowest cost-effectiveness ratio (4.63627), and the smallest ICER (4.63504). Sensitivity analyses proved the robustness of the results.ConclusionsBicyclol is the most cost-effective therapy and the preferred choice for treating anti-TB DILI.
Highlights
To evaluate the pharmacoeconomics of three therapeutic schemes in treating anti-tuberluosis therapy -induced liver injury
In 2014, about 1.5 million people died of tuberculosis, which has become the number one cause of death from infectious diseases in the world [1]
China has the second-highest incidence of tuberculosis in the world, with up to 1,300,000 new cases each year, accounting for 14.3% of new cases in the world
Summary
In the construction of a decision tree model, the efficacy and safety parameters came from the results of the randomized, controlled trial conducted here, the effect parameters were derived from expert advice, and the cost parameters, such as usage specification, number, and unit price, came from literature, expert advice, and so on. The study was carried out at the Sixth People’s Hospital of Zhengzhou, the Zhoukou Infectious Disease Hospital, and the Hebi Infectious Disease Hospital between November 2014 and January 2016. With the use of SPSS 22.0 statistical software, 225 patients were randomly assigned to 3 treatment groups at a 1:1:1 ratio. The study was in full compliance with the Declaration of Helsinki and good clinical research practice. The study was approved by the ethics committees of each hospital, and all patients provided written consents after they had been informed of the potential benefits and risks of the study
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
